CPT code 93261 represents the professional service of interrogating and evaluating a subcutaneous implantable cardioverter-defibrillator (S-ICD) lead system and preparing a report of findings. This evaluation is a key component of cardiac device management, supporting patient safety by confirming appropriate device function and identifying issues such as sensing problems, lead integrity concerns, or therapy delivery anomalies. Nationally, consistent reporting and billing for device interrogations affect quality tracking and resource allocation across outpatient and clinic settings.

Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with a concise overview of the code’s clinical context, typical sites of service, and administrative considerations relevant to billing and coding teams. It also outlines what to expect in benchmarking and policy updates when data is available, while noting where input data is not provided.

Readers will learn: the clinical purpose of CPT code 93261, the typical care settings where the service occurs, how major payers cover device interrogation services generally, and which operational elements—such as documentation and reporting—are central to accurate coding. Data not available in the input is explicitly noted where applicable.